|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the VRTX 8-K filed Jun 17, 2005. VX-680 Clinical Studies In addition to this Phase I study in hematologic cancers announced today, Merck is presently conducting two clinical studies of VX-680 in patients with recurrent or non-responsive solid tumors, or cancers for which standard therapy does not currently exist.
|
| |||||||